BioGend Therapeutics Co., Ltd. Statistics
BioGend Therapeutics Co., Ltd. (6733) Stock Statistics & Valuation Metrics
Total Valuation
BioGend Therapeutics Co., Ltd. has a market cap or net worth of TWD 2.82B. The enterprise value is TWD 2.51B.
- Market Cap
- TWD 2.82B
- Enterprise Value
- TWD 2.51B
Share Statistics
BioGend Therapeutics Co., Ltd. has 134,316,020 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 134,316,020
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
BioGend Therapeutics Co., Ltd.’s return on equity (ROE) is -0.11 and return on invested capital (ROIC) is -12.98%.
- Return on Equity (ROE)
- -0.11
- Return on Assets (ROA)
- -0.10
- Return on Invested Capital (ROIC)
- -12.98%
- Return on Capital Employed (ROCE)
- -0.14
- Revenue Per Employee
- 6.54M
- Profits Per Employee
- -2.49M
- Employee Count
- 34
- Asset Turnover
- 0.27
- Inventory Turnover
- 3.03
Valuation Ratios
The current PE Ratio of BioGend Therapeutics Co., Ltd. is -38.82. BioGend Therapeutics Co., Ltd.’s PEG ratio is -0.55.
- PE Ratio
- -38.82
- PS Ratio
- 11.81
- PB Ratio
- 2.57
- Price to FCF
- -55.69
- Price to Operating Cash Flow
- -57.98
- PEG Ratio
- -0.55
Income Statement
In the last 12 months, BioGend Therapeutics Co., Ltd. had revenue of 222.34M and earned -84.61M in profits. Earnings per share was -0.69.
- Revenue
- 222.34M
- Gross Profit
- 160.16M
- Operating Income
- -110.50M
- Pretax Income
- -103.61M
- Net Income
- -84.61M
- EBITDA
- -60.73M
- Earnings Per Share (EPS)
- -0.69
Cash Flow
In the last 12 months, operating cash flow was -47.23M and capital expenditures -2.93M, giving a free cash flow of -50.16M billion.
- Operating Cash Flow
- -47.23M
- Free Cash Flow
- -50.16M
- Free Cash Flow per Share
- -0.38
Dividends & Yields
BioGend Therapeutics Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.78%
- Earnings Yield
- -2.55%
Stock Price Statistics
- Beta
- 0.40
- 52-Week Price Change
- -49.06%
- 50-Day Moving Average
- 24.63
- 200-Day Moving Average
- 28.31
- Relative Strength Index (RSI)
- 21.07
- Average Volume (3m)
- 73.04K
Important Dates
BioGend Therapeutics Co., Ltd. upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 02, 2027
- Ex-Dividend Date
- ―
Financial Position
BioGend Therapeutics Co., Ltd. as a current ratio of 17.60, with Debt / Equity ratio of 0.89%
- Current Ratio
- 17.60
- Quick Ratio
- 17.03
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 3.48
- Interest Coverage Ratio
- -731.75
Taxes
In the past 12 months, BioGend Therapeutics Co., Ltd. has paid -8.31M in taxes.
- Income Tax
- -8.31M
- Effective Tax Rate
- 0.08
Enterprise Valuation
BioGend Therapeutics Co., Ltd. EV to EBITDA ratio is -49.26, with an EV/FCF ratio of -53.34.
- EV to Sales
- 11.31
- EV to EBITDA
- -49.26
- EV to Free Cash Flow
- -53.34
- EV to Operating Cash Flow
- -56.65
Balance Sheet
BioGend Therapeutics Co., Ltd. has TWD 849.79M in cash and marketable securities with TWD 4.76M in debt, giving a net cash position of TWD 845.03M billion.
- Cash & Marketable Securities
- TWD 849.79M
- Total Debt
- TWD 4.76M
- Net Cash
- TWD 845.03M
- Net Cash Per Share
- TWD 6.29
- Tangible Book Value Per Share
- TWD 7.67
Margins
Gross margin is 55.01%, with operating margin of -38.83%, and net profit margin of -29.75%.
- Gross Margin
- 55.01%
- Operating Margin
- -38.83%
- Pretax Margin
- -35.74%
- Net Profit Margin
- -29.75%
- EBITDA Margin
- -22.96%
- EBIT Margin
- -38.61%
Analyst Forecast
The average price target for BioGend Therapeutics Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 10.74%
- EPS Growth Forecast
- 21.61%
